KOD - Company ID 0001468748
Kodiak Sciences Inc. trades as KOD and has a market capitalization of $2.51 B, making it the #1978 largest US-listed company by market value. This page tracks Kodiak Sciences Inc. through 398 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| SCHEDULE 13G | - | 2026-04-27 |
| Annual report to shareholders | ARS | 2026-04-23 |
| Proxy materials | DEFA14A | 2026-04-22 |
| Proxy statement | DEF 14A | 2026-04-22 |
| Insider trade | 4 | 2026-04-16 |
"Kodiak's momentum has continued to build, highlighted by positive Phase 3 topline results from the GLOW2 study and multiple advancing late-stage and pipeline programs that together reinforce the company's differentiated molecules, platform and long term growth strategy," said Victor Perlroth , M.D., Chief Executive Officer of Kodiak Sciences .
Building on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% of sham-treated patients (p<0.0001).
Phase 3 GLOW2 diabetic retinopathy study – expected timeline to topline data
The largest companies sharing Kodiak Sciences Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Kodiak Sciences Inc. (KOD) has a market capitalization of $2.51 B as of 2026-07-09, ranking #1978 among US-listed companies.
In its latest fiscal year Kodiak Sciences Inc. reported a net loss of $229.97M.